Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study
Yi-Ting Chen, Chung-An Wang, Jui-Yi Chen, Vin-Cent Wu · 2026
Read Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study by Yi-Ting Chen, Chung-An Wang, Jui-Yi Chen, Vin-Cent Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224833.txt.
Description
Yi-Ting Chen, Chung-An Wang, Jui-Yi Chen, and Vin-Cent Wu weigh the safety of a diabetes drug class in people on peritoneal dialysis, in a 2026 study. The drugs, called SGLT2 inhibitors, protect heart and kidneys in many patients with kidney disease. Dialysis patients catch infections easily, though, so the balance of gain and risk was unclear.
Using a global health record network, the team mimicked a trial by matching drug users with non-users of like health. From nearly thirty thousand eligible patients, matched groups of about twenty-seven hundred each were compared. Outcomes covered death, severe infection, heart events, and dialysis-related belly infection. Emulated trials like this can guide care where real trials are unlikely to be run.
Catalog record
| CREATOR | Yi-Ting Chen, Chung-An Wang, Jui-Yi Chen, Vin-Cent Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |